Search 

One Top Chinese Pharma

JOT is a virtual company with its base operation in Jupiter, FL. JOT is in position to quickly come to market with a platform product effective to treat 12 or more indications including Alzheimer’s Disease. The proprietary patented product, JOTROL, is very safe, oral, naturally based and multi-functional. JOTROL will be very effective with high social and economic impact within a reasonable timeframe. Relationships have been developed with scientists at various institutions, such as University of Miami (“UM”), MIT, Harvard, Georgetown University and Murdoch Childrens Research Institute, AU. This setup has made it possible to gain access to laboratory work, scientific information, pre-clinical development and scientific expertise in an extremely cost effective and efficient way. JOT will conclude clinical trials by utilizing a contract manufacturer and Clinical Research Organizations, involvement by its scientific advisors as well as support from patient organizations thereby keeping its fixed overhead extremely low for a Biotech company. A Phase I trial is presently ongoing with results expected in Q1,2021. Two Phase II rare disease trials, are expected to be started in H2 of 2021 with possible accelerated approvals from FDA. Partial financing for those are expected to be received from NIH. A Phase II trial in Alzheimer’s is also planned to be executed in parallel. Financing for the Phase I study has been granted by NIA (National Institute of Aging). Financing for a larger Phase II study is also expected to be financed by a NIA consortium (up to $75 million). JOT is prepared to add a commercial organization to market its product in North America while out-licensing marketing and sales operations for the rest of the world.